
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc. has demonstrated strong performance in its advanced wound care product segment, particularly with Apligraf, which boasts an effective average selling price (ASP) that is four times higher than previous levels, positioning it as a competitive leader based on efficacy. Despite facing market volatility related to reimbursement structures, the company is experiencing monthly and daily increases in unit volumes, suggesting a potential trajectory for growth in future quarters. Additionally, the approved reimbursement rate of $127.28 per square centimeter for CY2026, which is slightly higher than previously proposed, reflects a favorable outlook for financial performance and may enhance the company's valuation significantly.
Bears say
Organogenesis Holdings Inc. has faced a significant share price decline of approximately 35% due to softer-than-expected fiscal year 2026 guidance, primarily attributed to reimbursement changes in the Advanced Wound Care market. The company anticipates a substantial 50% year-over-year decline in the first quarter of 2026, driven by the need to address product sizing waste and excess inventory. Furthermore, risks are compounded by potential issues such as lower-than-expected growth of its PuraPly product, regulatory hurdles, and challenges posed by Medicare pricing policies, leading to diminished confidence in future financial performance.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares